Employees: 413
Size Daewoong (003090.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $495M, the 347th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩15,660 on 18 Nov 2026.
Performance Over six months the shares fell 27.5%, against -12.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 5.7% over the last twelve months (peer median +13.0%); the operating margin is 11.4% (peer median 10.0%).
Valuation It trades at 4.1× forward earnings against a peer median of 18.2× (cheapest of 6).
Capital Return on invested capital runs 1.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩2.17T | ₩2.07T | ₩1.94T | ₩1.82T | ₩1.70T |
| Revenue growth | — | +7% | +7% | +7% | — |
| Gross profit | ₩1.14T | ₩1.09T | ₩1.04T | ₩925B | ₩893B |
| EBITDA | ₩340B | ₩323B | ₩338B | ₩248B | ₩255B |
| Net income | ₩171B | ₩175B | ₩57.9B | ₩153B | ₩103B |
| Free cash flow | -₩62.1B | -₩37.2B | -₩115B | ₩19.2B | ₩40.5B |
| Capital expenditure | ₩344B | ₩348B | ₩336B | ₩229B | ₩118B |
| Total debt | ₩1.00T | ₩878B | ₩718B | ₩477B | ₩495B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 003090.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.3% | -2.1% | 9th highest of 21 |
| 6-month return | -27.5% | -12.8% | 4th lowest of 21 |
| Distance from 52-week high | -48.8% | -34.8% | 5th lowest of 21 |
| Revenue growth (TTM) | +5.7% | +13.0% | 8th lowest of 20 |
| Operating margin | 11.4% | 10.0% | 9th highest of 20 |
| Forward P/E | 4.1× | 18.2× | cheapest of 6 |
| ROIC minus cost of capital | +1.3 pp | -2.7 pp | 7th highest of 18 |
| EV / EBITDA | 5.8× | 19.2× | 2nd cheapest of 5 |
| Net debt / EBITDA | 2.1× | 1.6× | most indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 4.1× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | n/a | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | n/a | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | n/a | 16.7% | +4.4% |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 21.3× | 22.1% | +3.5% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | n/a | 5.9% | -4.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 7.3× | -17.2% | +6.3% |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | n/a | -5.4% | +7.6% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | n/a | 8.9% | +9.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | n/a | 3.3% | -1.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 18.2× | n/a | n/a |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | n/a | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 15.1× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | n/a | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | n/a | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | n/a | -4.7% | +105.3% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | n/a | -6.1% | +9.6% |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | n/a | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 42.2× | n/a | n/a |